Keyphrases
Randomized Controlled Trial
100%
Childhood Acute Lymphoblastic Leukemia
100%
6-mercaptopurine (6-MP)
100%
Consolidation Treatment
100%
Control Arm
60%
Minimal Residual Disease
40%
Event-free Survival
40%
Myelosuppression
20%
Treatment Interruption
20%
One Dose
20%
Consolidation Therapy
20%
Event Probability
20%
High-risk Acute Leukemia
20%
Medicine and Dentistry
Randomized Controlled Trial
100%
Arm
100%
Acute Lymphoblastic Leukemia
100%
Mercaptopurine
100%
Minimal Residual Disease
25%
Event Free Survival
25%
Treatment Interruption
12%
Bone Marrow Suppression
12%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Controlled Trial
100%
Mercaptopurine
100%
Acute Lymphoblastic Leukemia
100%
Minimal Residual Disease
40%
Event Free Survival
40%
Bone Marrow Suppression
20%
Biochemistry, Genetics and Molecular Biology
Randomized Controlled Trial
100%
Mercaptopurine
100%
Event Free Survival
40%
Treatment Interruption
20%
Immunology and Microbiology
Arm
100%
Event Free Survival
25%
Agricultural and Biological Sciences